Bardia Moayedi
Snell & Wilmer L.L.P.
Recognized since 2023
San Diego, California
Corporate Law
Mergers and Acquisitions Law
Venture Capital Law
Bardia Moayedi is a corporate and securities partner at Snell & Wilmer, a full-service business law firm with more than 450 attorneys practicing in 16 locations throughout the United States and in Mexico, including three locations in California. He is chair of the firm's Technology Industry Group and co-chair of the firm's Life Sciences Industry Group. He primarily advises emerging growth and public companies throughout their life cycles as well as venture capital and private equity firms, particularly in the life sciences, high-technology, financial technology, food and beverage, and clean-technology industries.
Bardia has significant experience representing companies and financial firms in a broad range of general corporate governance and transactional matters, including venture capital financings, mergers and acquisitions, debt offerings, spin-offs/divestitures, joint ventures, IPOs, follow-on offerings, and tender offers. He is a trusted advisor, often serving as the go-to outside counsel or lead counsel to his clients.
Prior to attending law school, Bardia worked at a prominent investment bank, where he focused on hedge funds and private equity funds. As an undergraduate, he played ice and roller hockey at UCLA.
Representative Experience
Startups and Venture Capital
- Extensive experience representing companies and venture capital firms in numerous convertible note, SAFE and seed financings
- Extensive experience representing companies and venture capital firms in numerous Series A through pre-IPO preferred stock financings
Mergers and Acquisitions
- Represented a therapeutics company in its over $600 million acquisition by a Fortune 100 company
- Represented a medical device company in its $400 million acquisition by a Fortune 100 company
- Represented a biotherapeutics company in its $300 million acquisition by a Fortune 100 company
- Represented a high-technology company in its over $250 million acquisition by a Fortune 100 company
- Represented a pharmaceutical company in its over $200 million acquisition by a publicly traded company
- Represented a high-technology company in its $200 million acquisition by a publicly traded company
Capital Markets
- Represented a clinical-stage immunotherapy company in its over $200 million IPO
- Represented a high-technology company it its over $100 million IPO
- Represented a medical device company in its over $70 million IPO
- Represented a biotherapeutics company in its over $50 million IPO
- Represented a clinical-stage biosimilars company in its $50 million IPO
- Represented a publicly traded company in its over $200 million tender offer
- Represented a publicly traded company in its $200 million tender offer
Recent Client News
- Snell & Wilmer Advises Fintech Platform Greenwood in Two-Year NIL Deal with the Black-Owned Digital Bank’s Newest Brand Ambassador
- Snell & Wilmer Advises Fintech Startup Greenwood in Acquisition of Valence
- Snell & Wilmer Advises Bio-Systems Company TARGAN as it Secures $35 Million in Series C Financing
- Snell & Wilmer Advises Technology Food Data Company Galley Solutions as it Raised $14.2 Million in Series A Funding
- Snell & Wilmer Advises Fintech Startup Greenwood in Acquisition of The Gathering Spot
- Snell & Wilmer Represents Software Development Company Flywheel Software in Growth Equity Investment from The Jordan Company, L.P.
- Snell & Wilmer Represents Hothand Inc. in Acquisition By Fintech Company AppTech Payments Corp.
- Snell & Wilmer Represents Microbrewery Mission Brewery in Acquisition by California Investment Company
- Snell & Wilmer Represents Contract Development and Manufacturing Organization Drug Delivery Experts in Acquisition by Pace Analytical
- Snell & Wilmer Advises Client Blueprint Equity as it Leads $8M Series A Funding of Tovuti, Inc.
- Snell & Wilmer Represents Advertising Technology Company Proper Media, LLC in Acquisition by Sovrn Holdings, Inc.
- Snell & Wilmer Represents Biotech Nexturn Bio, Inc. in its Majority Stake Investment in RosVivo Therapeutics Inc.
- E-mail: bmoayedi@swlaw.com
- Direct Phone Number: 858-434-5009
- Phone Number: 858-434-5020
- Lawyer Page: https://www.swlaw.com/people/bardia_moayedi
- Executive Center Del Mar, Suite 300
12230 El Camino Real
San Diego, CA 92130 - Plaza Tower, Suite 1400
600 Anton Boulevard
Costa Mesa, CA 92626-7689
- Farsi
- University of California - Los Angeles, B.A.
- University of San Diego, J.D.
- California, California
- Business Forum International, San Diego Chapter - Executive Committee Member
- Iranian American Bar Association - Member
- San Diego Venture Group - Member
- SDSU ZIP Launchpad - Advisor
- UC Hastings Start-up Legal Garage - Advisor
- UC Irvine Applied Innovation Incubator - Advisor
5 The Best Lawyers in America® awards
- Corporate Law
- Mergers and Acquisitions Law
- Venture Capital Law
- 2022 40 Under 40 Winner, San Diego Metro (2022)
- 40 Next Top Business Leaders Under 40 Finalist, San Diego Business Journal (2022)
- 2022 Top Attorneys, San Diego Metro (2022)
- San Diego Super Lawyers, Rising Stars Edition, Corporate and Securities (2022)
- Leaders in Law 2021 Finalist, San Diego Business Journal (2021)
- 2021 Men of Influence Winner, San Diego Metro (2021)
- 2021 40 Next Top Business Leaders Under 40 Winner, San Diego Business Journal (2021)
- CALI Excellence Award, High-Tech Startups (2014)
Your browser is not fully compatible with our automatic printer friendly formatting.
Please use the print button to print this profile page.